IO Biotech (IOBT) Competitors $0.90 -0.04 (-4.26%) Closing price 01/31/2025 03:54 PM EasternExtended Trading$0.90 0.00 (0.00%) As of 01/31/2025 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends IOBT vs. CCCC, BNTC, CMPS, AMLX, CGC, URGN, ATAI, AMRN, FHTX, and NGNEShould you be buying IO Biotech stock or one of its competitors? The main competitors of IO Biotech include C4 Therapeutics (CCCC), Benitec Biopharma (BNTC), COMPASS Pathways (CMPS), Amylyx Pharmaceuticals (AMLX), Canopy Growth (CGC), UroGen Pharma (URGN), Atai Life Sciences (ATAI), Amarin (AMRN), Foghorn Therapeutics (FHTX), and Neurogene (NGNE). These companies are all part of the "pharmaceutical products" industry. IO Biotech vs. C4 Therapeutics Benitec Biopharma COMPASS Pathways Amylyx Pharmaceuticals Canopy Growth UroGen Pharma Atai Life Sciences Amarin Foghorn Therapeutics Neurogene C4 Therapeutics (NASDAQ:CCCC) and IO Biotech (NASDAQ:IOBT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, community ranking, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership. Do insiders and institutionals have more ownership in CCCC or IOBT? 78.8% of C4 Therapeutics shares are owned by institutional investors. Comparatively, 54.8% of IO Biotech shares are owned by institutional investors. 8.6% of C4 Therapeutics shares are owned by company insiders. Comparatively, 2.3% of IO Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media favor CCCC or IOBT? In the previous week, IO Biotech had 3 more articles in the media than C4 Therapeutics. MarketBeat recorded 4 mentions for IO Biotech and 1 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 1.87 beat IO Biotech's score of 1.21 indicating that C4 Therapeutics is being referred to more favorably in the media. Company Overall Sentiment C4 Therapeutics Very Positive IO Biotech Positive Which has stronger earnings & valuation, CCCC or IOBT? IO Biotech has lower revenue, but higher earnings than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than IO Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioC4 Therapeutics$20.76M11.80-$132.49M-$1.70-2.04IO BiotechN/AN/A-$86.08M-$1.37-0.66 Do analysts prefer CCCC or IOBT? C4 Therapeutics presently has a consensus target price of $11.60, indicating a potential upside of 234.29%. IO Biotech has a consensus target price of $9.33, indicating a potential upside of 937.04%. Given IO Biotech's stronger consensus rating and higher probable upside, analysts plainly believe IO Biotech is more favorable than C4 Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score C4 Therapeutics 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60IO Biotech 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, CCCC or IOBT? C4 Therapeutics has a beta of 2.96, indicating that its stock price is 196% more volatile than the S&P 500. Comparatively, IO Biotech has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500. Is CCCC or IOBT more profitable? IO Biotech has a net margin of 0.00% compared to C4 Therapeutics' net margin of -313.35%. C4 Therapeutics' return on equity of -42.45% beat IO Biotech's return on equity.Company Net Margins Return on Equity Return on Assets C4 Therapeutics-313.35% -42.45% -27.55% IO Biotech N/A -86.56%-75.24% Does the MarketBeat Community believe in CCCC or IOBT? C4 Therapeutics received 5 more outperform votes than IO Biotech when rated by MarketBeat users. However, 91.67% of users gave IO Biotech an outperform vote while only 39.13% of users gave C4 Therapeutics an outperform vote. CompanyUnderperformOutperformC4 TherapeuticsOutperform Votes2739.13% Underperform Votes4260.87% IO BiotechOutperform Votes2291.67% Underperform Votes28.33% SummaryC4 Therapeutics and IO Biotech tied by winning 8 of the 16 factors compared between the two stocks. Get IO Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for IOBT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IOBT vs. The Competition Export to ExcelMetricIO BiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$61.93M$6.86B$5.56B$9.11BDividend YieldN/A2.90%5.31%3.98%P/E Ratio-0.669.9789.9918.25Price / SalesN/A227.221,221.9274.93Price / CashN/A73.5045.9637.70Price / Book0.455.275.124.71Net Income-$86.08M$136.98M$111.09M$224.24M7 Day Performance-4.76%-0.62%2.38%1.08%1 Month Performance-2.17%0.15%3.20%1.51%1 Year Performance-50.00%7.68%24.70%20.44% IO Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IOBTIO Biotech3.7773 of 5 stars$0.90-4.3%$9.33+937.0%-48.3%$61.93MN/A-0.6630Short Interest ↓Positive NewsCCCCC4 Therapeutics2.1143 of 5 stars$3.62-0.3%$10.67+194.7%-43.9%$255.54M$20.76M-2.13150Positive NewsBNTCBenitec Biopharma2.6409 of 5 stars$10.78+0.3%$24.43+126.6%+308.9%$250.31M$80,000.000.0020News CoverageCMPSCOMPASS Pathways2.1383 of 5 stars$3.61-7.2%$33.60+830.7%-61.8%$247.00MN/A-1.64120AMLXAmylyx Pharmaceuticals3.0871 of 5 stars$3.49-3.1%$7.33+110.1%-77.2%$246.77M$196.49M-0.91200Short Interest ↑Analyst RevisionNews CoverageCGCCanopy Growth1.2488 of 5 stars$2.09-5.9%$3.50+67.5%-57.4%$246.43M$220.27M-0.421,029Upcoming EarningsShort Interest ↓News CoveragePositive NewsURGNUroGen Pharma4.0591 of 5 stars$10.48+2.3%$43.70+317.0%-29.9%$245.76M$82.71M-3.33200ATAIAtai Life Sciences2.4466 of 5 stars$1.45-8.2%$9.00+520.7%-12.9%$243.31M$310,000.00-1.7980Analyst ForecastNews CoverageAMRNAmarin0.4011 of 5 stars$0.59-5.6%N/A-49.0%$243.12M$306.91M-6.58360FHTXFoghorn Therapeutics2.5675 of 5 stars$4.12+1.5%$13.80+235.0%+31.8%$229.03M$34.15M-2.15120Analyst UpgradeShort Interest ↓Analyst RevisionNews CoverageNGNENeurogene3.2281 of 5 stars$15.08+0.1%$60.83+303.4%-47.4%$223.94MN/A0.0090 Related Companies and Tools Related Companies C4 Therapeutics Competitors Benitec Biopharma Competitors COMPASS Pathways Competitors Amylyx Pharmaceuticals Competitors Canopy Growth Competitors UroGen Pharma Competitors Atai Life Sciences Competitors Amarin Competitors Foghorn Therapeutics Competitors Neurogene Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IOBT) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IO Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IO Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
